{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:56:50Z","timestamp":1793995010699,"version":"4.8.0"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,23]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to determine the frequency and types of infections in hospitalized children with childhood-onset systemic lupus erythematosus (cSLE), and to identify risk factors for intensive care unit (ICU) admission and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study of youth aged 2 to 21 years using International Classification of Diseases (ICD) codes for SLE assigned during admission to a hospital participating in the Pediatric Health Information System, a database of United States children\u2019s hospitals, from 2009 to 2021. Generalized linear mixed effects models were used to identify risk factors for ICU admission and mortality among children hospitalized with infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 8588 children with cSLE and \u2265 1 hospitalization. Among this cohort, there were 26,269 hospitalizations, of which 13% had codes for infections, a proportion that increased over time (<jats:italic>P<\/jats:italic>= 0.04). Bacterial pneumonia was the most common hospitalized infection. In-hospital mortality occurred in 0.4% (n = 103) of cSLE hospitalizations for any indication and 2% of hospitalizations for infection (n = 60). The highest mortality rates occurred with<jats:italic>Pneumocystis jirovecii<\/jats:italic>pneumonia (21%) and other fungal infections (21%). Lupus nephritis (LN) and endstage renal disease (ESRD) were associated with increased odds of ICU admission (odds ratio [OR] 1.47 [95% CI 1.2-1.8] and OR 2.40 [95% CI 1.7-3.4]) among children admitted for serious infection. ESRD was associated with higher mortality (OR 2.34 [95% CI 1.1-4.9]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hospitalizations with ICD codes for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. LN and ESRD were risk factors for poor outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1219","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T12:20:23Z","timestamp":1711974023000},"page":"891-898","source":"Crossref","is-referenced-by-count":14,"title":["Hospitalization and Mortality Due to Infection Among Children and Adolescents With Systemic Lupus Erythematosus in the United States"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-5697","authenticated-orcid":false,"given":"Jordan E.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Faino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mersine A.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-1781","authenticated-orcid":false,"given":"Esi M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2024090105300581000_51.9.891.1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024090105300581000_51.9.891.2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313493032"},{"key":"2024090105300581000_51.9.891.3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11926-016-0561-4","article-title":"Infection and lupus: which causes which?","volume":"18","author":"Doaty","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2024090105300581000_51.9.891.4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314563817"},{"key":"2024090105300581000_51.9.891.5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.berh.2018.02.001","article-title":"Juvenile-onset systemic lupus erythematosus (jSLE) \u2013 pathophysiological concepts and treatment options","volume":"31","author":"Hedrich","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024090105300581000_51.9.891.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20179"},{"key":"2024090105300581000_51.9.891.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.10072"},{"key":"2024090105300581000_51.9.891.8","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/acr.23219","article-title":"Serious infection rates among children with systemic lupus erythematosus enrolled in Medicaid","volume":"69","author":"Hiraki","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2024090105300581000_51.9.891.9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/QCO.0000000000000246","article-title":"Pneumococcal vaccination","volume":"29","author":"Cill\u00f3niz","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2024090105300581000_51.9.891.10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apa.15594","article-title":"Impact of PCV-13 vaccine on invasive pneumococcal disease in hospitalised children: a multi-institutional analysis","volume":"110","author":"Dreyzin","year":"2021","journal-title":"Acta Paediatr"},{"key":"2024090105300581000_51.9.891.11","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2024090105300581000_51.9.891.12","doi-asserted-by":"crossref","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024090105300581000_51.9.891.13","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/rheumatology\/keab626","article-title":"New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases","volume":"61","author":"Ong","year":"2022","journal-title":"Rheumatology"},{"key":"2024090105300581000_51.9.891.14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1640"},{"key":"2024090105300581000_51.9.891.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130592"},{"key":"2024090105300581000_51.9.891.16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000711"},{"key":"2024090105300581000_51.9.891.17","unstructured":"American Academy of Pediatrics . Immunizations. [Internet. Accessed April 16, 2024.] Available from: www.aap.org\/en\/patient-care\/immunizations\/"},{"key":"2024090105300581000_51.9.891.18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2024090105300581000_51.9.891.19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/0961203319882498","article-title":"Risk factors of infection-associated mortality in children with lupus nephritis in under-resourced areas","volume":"28","author":"Rianthavorn","year":"2019","journal-title":"Lupus"},{"key":"2024090105300581000_51.9.891.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.07.011"},{"key":"2024090105300581000_51.9.891.21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024090105300581000_51.9.891.22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/acr.24584","article-title":"Pneumocystis jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2024090105300581000_51.9.891.23","doi-asserted-by":"crossref","first-page":"152106","DOI":"10.1016\/j.semarthrit.2022.152106","article-title":"Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus","volume":"57","author":"Boone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024090105300581000_51.9.891.24","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0961203317703494","article-title":"Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse","volume":"26","author":"Kapoor","year":"2017","journal-title":"Lupus"},{"key":"2024090105300581000_51.9.891.25","doi-asserted-by":"crossref","first-page":"e0144918","DOI":"10.1371\/journal.pone.0144918","article-title":"National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia","volume":"11","author":"Murray","year":"2016","journal-title":"PLOS One"},{"key":"2024090105300581000_51.9.891.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2024090105300581000_51.9.891.27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trsl.2020.12.007","article-title":"COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease","volume":"232","author":"Fernandez-Ruiz","year":"2021","journal-title":"Transl Res"},{"key":"2024090105300581000_51.9.891.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4492"},{"key":"2024090105300581000_51.9.891.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222241"},{"key":"2024090105300581000_51.9.891.30","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312470186"},{"key":"2024090105300581000_51.9.891.31","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000574"},{"key":"2024090105300581000_51.9.891.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.08.009"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T12:30:38Z","timestamp":1725193838000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.3899\/jrheum.2023-1219"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1219","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}